The UL24 consensus regions of bovine herpesvirus 2 isolate 554 and clinical isolates of herpes simplex viruses 1 and 2

Jelic, Irena; May, J. T.

doi:10.2323/jgam.49.363

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One gene UL24 , is considered to be a core herpesvirus gene and is conserved among most of the herpes viruses [20,21], and null mutations or mutations in the conversed regions of UL24 can confer a syncytial phenotype and result in decreased viral yields in cultured cells, indicating that UL24 is important for efficient viral replication [22,23]. In addition, UL24 protein has the ability to elicit a specific antibody response [24].…”

Section: Introductionmentioning

confidence: 99%

Attenuated Salmonella typhimurium delivering DNA vaccine encoding duck enteritis virus UL24 induced systemic and mucosal immune responses and conferred good protection against challenge

Jia

Huang

et al. 2012

Vet Res

View full text Add to dashboard Cite

Orally delivered DNA vaccines against duck enteritis virus (DEV) were developed using live attenuated Salmonella typhimurium (SL7207) as a carrier and Escherichia coli heat labile enterotoxin B subunit (LTB) as a mucosal adjuvant. DNA vaccine plasmids pVAX-UL24 and pVAX-LTB-UL24 were constructed and transformed into attenuated Salmonella typhimurium SL7207 resulting SL7207 (pVAX-UL24) and SL7207 (pVAX-LTB-UL24) respectively. After ducklings were orally inoculated with SL7207 (pVAX-UL24) or SL7207 (pVAX-LTB-UL24), the anti-DEV mucosal and systemic immune responses were recorded. To identify the optimum dose that confers maximum protection, we used different doses of the candidate vaccine SL7207 (pVAX-LTB-UL24) during oral immunization. The strongest mucosal and systemic immune responses developed in the SL7207 (pVAX-LTB-UL24) (1011 CFU) immunized group. Accordingly, oral immunization of ducklings with SL7207 (pVAX-LTB-UL24) showed superior efficacy of protection (60-80%) against a lethal DEV challenge (1000 LD50), compared with the limited survival rate (40%) of ducklings immunized with SL7207 (pVAX-UL24). Our study suggests that the SL7207 (pVAX-LTB-UL24) can be a candidate DEV vaccine.

show abstract